Bianchi Porro G, Lazzaroni M, Lodola E
Int J Clin Pharmacol Ther Toxicol. 1983 Jul;21(7):374-7.
Blood concentrations and pharmacokinetic parameters of cimetidine were studied in 16 patients with liver cirrhosis and in 8 apparently healthy subjects. The drug was administered orally as a single dose of 200 mg. Four patients of both groups were treated with cimetidine orally and intravenously. No statistically significant difference was observed between pharmacokinetic parameters of cimetidine obtained from control subjects and those from patients with liver cirrhosis. The pharmacokinetic parameters of cimetidine in patients with liver cirrhosis did not significantly differ from those of normal patients even if separately calculated with respect to serum albumin and total serum bilirubin.
在16例肝硬化患者和8名健康受试者中研究了西咪替丁的血药浓度和药代动力学参数。以200mg单剂量口服给药。两组各有4例患者接受了西咪替丁的口服和静脉给药治疗。从健康受试者和肝硬化患者获得的西咪替丁药代动力学参数之间未观察到统计学上的显著差异。即使分别根据血清白蛋白和总血清胆红素进行计算，肝硬化患者中西咪替丁的药代动力学参数与正常患者的参数也无显著差异。
